<div class="container">

<table style="width: 100%;"><tr>
<td>aidscd4</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>CD4 Cells Count Data in Aids Randomized Controlled Clinical Trial.</h2>

<h3>Description</h3>

<p>The data are from a randomized, double-blind study of acquired immune
deficiency syndrome (AIDS) patients with advanced immune suppression
(cluster of differentiation 4 (CD4) cells count of less than or equal to 50
cells/mm3) (Henry et al., 1998; Fitzmaurice et al., 2011). Patients in the
AIDS Clinical Trial Group Study 193A were randomized to dual or triple
combinations of human immunodeficiency virus-1 reverse transcriptase
inhibitors. Specifically, patients were randomized to one of four daily
regimens.
</p>


<h3>Format</h3>

<p>A data frame with 4708 observations on the following 7 variables:
</p>

<dl>
<dt><code>id</code></dt>
<dd>
<p>patient identifier; in total there are 1177 patients.</p>
</dd>
<dt><code>weekc</code></dt>
<dd>
<p>nominal visit variable (weeks 8, 16, 24, 32).</p>
</dd>
<dt><code>treatment</code></dt>
<dd>
<p>allocated treatment regimens; 1 = zidovudine
alternating monthly with 400mg didanosine, 2 = zidovudine plus
2.25mg of zalcitabine, 3 = zidovudine plus 400mg of didanosine,
and 4 = zidovudine plus 400mg of didanosine plus 400mg of
nevirapine.</p>
</dd>
<dt><code>age</code></dt>
<dd>
<p>patients' age (years).</p>
</dd>
<dt><code>sex</code></dt>
<dd>
<p>patients' sex (1 = male, 0 = female)</p>
</dd>
<dt><code>cd4.bl</code></dt>
<dd>
<p>baseline value of CD4 cells count + 1.</p>
</dd>
<dt><code>cd4</code></dt>
<dd>
<p>CD4 cells count + 1.</p>
</dd>
</dl>
<h3>Source</h3>

<p><a href="https://www.hsph.harvard.edu/fitzmaur/ala/">https://www.hsph.harvard.edu/fitzmaur/ala/</a>
</p>


<h3>References</h3>


<ul>
<li>
<p> Henry, K., Erice, A., Tierney, C., Balfour, H.H. Jr., Fischl, M.A.,
Kmack, A., Liou, S.H., Kenton, A., Hirsch, M.S., Phair, J.,
Martinez, A., Kahn, J.O., for the AIDS Clinical Trial Group 193A
Study Team. (1998). A randomized, controlled, double-blind study
comparing the survival benefit of four different reverse
transcriptase inhibitor therapies (three-drug, two-drug, and
alternating drug) for the treatment of advanced AIDS.
<em>Journal of Acquired Immune Deficiency Syndromes and
Human Retrovirology</em>, 19, 339-349,
<a href="https://doi.org/10.1097/00042560-199812010-00004">https://doi.org/10.1097/00042560-199812010-00004</a>.
</p>
</li>
<li>
<p> Fitzmaurice, G.M., Laird, N.M., and Ware, J.H. (2011).
<em>Applied Longitudinal Analysis 2nd ed.</em>, Wiley, New York,
<a href="https://doi.org/10.1002/9781119513469">https://doi.org/10.1002/9781119513469</a>.
</p>
</li>
</ul>
<h3>Examples</h3>

<pre><code class="language-R">data(aidscd4)

</code></pre>


</div>